Pay in 4 interest-free payments of $5.56 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
Critics also argue that large, concentrated PBMs push contracts onto plan sponsors that limit the sponsors visibility into rebate structures and net drug costs
As many as eight of every 10 patients who received elecoglipron reached their guideline-recommended glycaemic targets, which we know are linked with better outcomes and long-term health. Sharon Barr, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca said: Our ambition is to have a portfolio that can tackle many of the cardiovascular, renal and metabolic diseases that are leading causes of death worldwide
doi: 10.1086/596211 199 RosadiniC
Divergent leptin signaling in proglucagon neurons of the nucleus of the solitary tract in mice and rats
US$ 24.18
US$ 22.62
US$ 21.39
